Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
Academy, ADC, Alette, Alzheimer, Austria, background, bankruptcy, Boston, Bristol, cervical, challenge, Chapter, characterized, clearance, College, compatibility, conjugate, CRC, CSCO, customary, Dear, Dermatology, division, dossier, download, Dr, Durable, earlier, edition, ENA, endanger, Europe, gBRCA, HCP, Head, holder, Huang, insignificant, interrupted, irrespective, Italy, label, load, marker, Milan, multicohort, Neuropsychopharmacology, nivolumab, NORA, Notably, OS, osimertinib, pembrolizumab, Peter, pharmacokinetic, PK, poor, prescription, Punishment, ratably, reclassification, reclassified, recurrent, remeasurement, resistance, retrieve, Seagen, SITC, Squibb, strong, subsidy, SVP, symposium, timeline, tisotumab, TIVDAK, transition, uncured, vedotin, Venereology, Verbeek, Vienna, VYGART, worse
Removed:
accessing, breakthrough, care, caution, Center, competing, compound, confidentiality, continually, covering, demonstrated, department, director, disclose, eleventh, enactment, endpoint, implement, implementing, introduced, involving, large, list, margetuximab, NaN, NDA, negotiation, notice, obtaining, PIPL, prime, reimbursement, relation, restrictive, shareholder, similarly, supported, terminate, topline, twelve, uncertainty, undergo, undertaken, written
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view